bluebird bio Competitors

Fate Therapeutics (NASDAQ:FATE) and bluebird bio (NASDAQ:BLUE) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability and valuation.

Risk and Volatility

Fate Therapeutics has a beta of 1.88, meaning that its stock price is 88% more volatile than the S&P 500. Comparatively, bluebird bio has a beta of 1.89, meaning that its stock price is 89% more volatile than the S&P 500.

Profitability

This table compares Fate Therapeutics and bluebird bio's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Fate Therapeutics and bluebird bio, as provided by MarketBeat.com.

Fate Therapeutics currently has a consensus price target of $104.3750, suggesting a potential upside of 31.85%. bluebird bio has a consensus price target of $68.4667, suggesting a potential upside of 142.36%. Given bluebird bio's higher possible upside, analysts plainly believe bluebird bio is more favorable than Fate Therapeutics.

Valuation & Earnings

This table compares Fate Therapeutics and bluebird bio's revenue, earnings per share and valuation.

Fate Therapeutics has higher earnings, but lower revenue than bluebird bio. Fate Therapeutics is trading at a lower price-to-earnings ratio than bluebird bio, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

99.7% of Fate Therapeutics shares are held by institutional investors. Comparatively, 94.3% of bluebird bio shares are held by institutional investors. 21.4% of Fate Therapeutics shares are held by company insiders. Comparatively, 3.6% of bluebird bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Fate Therapeutics beats bluebird bio on 9 of the 14 factors compared between the two stocks.

Denali Therapeutics (NASDAQ:DNLI) and bluebird bio (NASDAQ:BLUE) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability and valuation.

Risk and Volatility

Denali Therapeutics has a beta of 2, meaning that its stock price is 100% more volatile than the S&P 500. Comparatively, bluebird bio has a beta of 1.89, meaning that its stock price is 89% more volatile than the S&P 500.

Profitability

This table compares Denali Therapeutics and bluebird bio's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Denali Therapeutics and bluebird bio, as provided by MarketBeat.com.

Denali Therapeutics currently has a consensus price target of $65.1111, suggesting a potential upside of 14.98%. bluebird bio has a consensus price target of $68.4667, suggesting a potential upside of 142.36%. Given bluebird bio's higher possible upside, analysts plainly believe bluebird bio is more favorable than Denali Therapeutics.

Valuation & Earnings

This table compares Denali Therapeutics and bluebird bio's revenue, earnings per share and valuation.

Denali Therapeutics has higher earnings, but lower revenue than bluebird bio. Denali Therapeutics is trading at a lower price-to-earnings ratio than bluebird bio, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

68.2% of Denali Therapeutics shares are held by institutional investors. Comparatively, 94.3% of bluebird bio shares are held by institutional investors. 19.3% of Denali Therapeutics shares are held by company insiders. Comparatively, 3.6% of bluebird bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Denali Therapeutics beats bluebird bio on 9 of the 14 factors compared between the two stocks.

Kodiak Sciences (NASDAQ:KOD) and bluebird bio (NASDAQ:BLUE) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability and valuation.

Risk and Volatility

Kodiak Sciences has a beta of 1.42, meaning that its stock price is 42% more volatile than the S&P 500. Comparatively, bluebird bio has a beta of 1.89, meaning that its stock price is 89% more volatile than the S&P 500.

Insider and Institutional Ownership

82.3% of Kodiak Sciences shares are held by institutional investors. Comparatively, 94.3% of bluebird bio shares are held by institutional investors. 39.3% of Kodiak Sciences shares are held by company insiders. Comparatively, 3.6% of bluebird bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Kodiak Sciences and bluebird bio's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Kodiak Sciences and bluebird bio, as provided by MarketBeat.com.

Kodiak Sciences currently has a consensus price target of $129.9091, suggesting a potential upside of 11.42%. bluebird bio has a consensus price target of $68.4667, suggesting a potential upside of 142.36%. Given bluebird bio's stronger consensus rating and higher possible upside, analysts plainly believe bluebird bio is more favorable than Kodiak Sciences.

Valuation & Earnings

This table compares Kodiak Sciences and bluebird bio's revenue, earnings per share and valuation.

Kodiak Sciences has higher earnings, but lower revenue than bluebird bio. Kodiak Sciences is trading at a lower price-to-earnings ratio than bluebird bio, indicating that it is currently the more affordable of the two stocks.

Summary

bluebird bio beats Kodiak Sciences on 7 of the 13 factors compared between the two stocks.

Vir Biotechnology (NASDAQ:VIR) and bluebird bio (NASDAQ:BLUE) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability and dividends.

Volatility and Risk

Vir Biotechnology has a beta of -0.99, meaning that its stock price is 199% less volatile than the S&P 500. Comparatively, bluebird bio has a beta of 1.89, meaning that its stock price is 89% more volatile than the S&P 500.

Insider & Institutional Ownership

54.5% of Vir Biotechnology shares are owned by institutional investors. Comparatively, 94.3% of bluebird bio shares are owned by institutional investors. 37.2% of Vir Biotechnology shares are owned by company insiders. Comparatively, 3.6% of bluebird bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Vir Biotechnology and bluebird bio's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent recommendations for Vir Biotechnology and bluebird bio, as provided by MarketBeat.

Vir Biotechnology currently has a consensus price target of $65.2857, suggesting a potential upside of 53.98%. bluebird bio has a consensus price target of $68.4667, suggesting a potential upside of 142.36%. Given bluebird bio's higher possible upside, analysts plainly believe bluebird bio is more favorable than Vir Biotechnology.

Earnings and Valuation

This table compares Vir Biotechnology and bluebird bio's revenue, earnings per share and valuation.

Vir Biotechnology has higher earnings, but lower revenue than bluebird bio. Vir Biotechnology is trading at a lower price-to-earnings ratio than bluebird bio, indicating that it is currently the more affordable of the two stocks.

Summary

bluebird bio beats Vir Biotechnology on 8 of the 14 factors compared between the two stocks.

Halozyme Therapeutics (NASDAQ:HALO) and bluebird bio (NASDAQ:BLUE) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability and dividends.

Volatility and Risk

Halozyme Therapeutics has a beta of 1.77, meaning that its stock price is 77% more volatile than the S&P 500. Comparatively, bluebird bio has a beta of 1.89, meaning that its stock price is 89% more volatile than the S&P 500.

Insider & Institutional Ownership

98.5% of Halozyme Therapeutics shares are owned by institutional investors. Comparatively, 94.3% of bluebird bio shares are owned by institutional investors. 2.6% of Halozyme Therapeutics shares are owned by company insiders. Comparatively, 3.6% of bluebird bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Halozyme Therapeutics and bluebird bio's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent recommendations for Halozyme Therapeutics and bluebird bio, as provided by MarketBeat.

Halozyme Therapeutics currently has a consensus price target of $42.9167, suggesting a potential upside of 8.62%. bluebird bio has a consensus price target of $68.4667, suggesting a potential upside of 142.36%. Given bluebird bio's higher possible upside, analysts plainly believe bluebird bio is more favorable than Halozyme Therapeutics.

Earnings and Valuation

This table compares Halozyme Therapeutics and bluebird bio's revenue, earnings per share and valuation.

Halozyme Therapeutics has higher revenue and earnings than bluebird bio. Halozyme Therapeutics is trading at a lower price-to-earnings ratio than bluebird bio, indicating that it is currently the more affordable of the two stocks.

Summary

Halozyme Therapeutics beats bluebird bio on 10 of the 14 factors compared between the two stocks.

Adaptive Biotechnologies (NASDAQ:ADPT) and bluebird bio (NASDAQ:BLUE) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability and dividends.

Volatility and Risk

Adaptive Biotechnologies has a beta of 0.35, meaning that its stock price is 65% less volatile than the S&P 500. Comparatively, bluebird bio has a beta of 1.89, meaning that its stock price is 89% more volatile than the S&P 500.

Insider & Institutional Ownership

80.8% of Adaptive Biotechnologies shares are owned by institutional investors. Comparatively, 94.3% of bluebird bio shares are owned by institutional investors. 22.2% of Adaptive Biotechnologies shares are owned by company insiders. Comparatively, 3.6% of bluebird bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Adaptive Biotechnologies and bluebird bio's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent recommendations for Adaptive Biotechnologies and bluebird bio, as provided by MarketBeat.

Adaptive Biotechnologies currently has a consensus price target of $61.40, suggesting a potential upside of 61.03%. bluebird bio has a consensus price target of $68.4667, suggesting a potential upside of 142.36%. Given bluebird bio's higher possible upside, analysts plainly believe bluebird bio is more favorable than Adaptive Biotechnologies.

Earnings and Valuation

This table compares Adaptive Biotechnologies and bluebird bio's revenue, earnings per share and valuation.

Adaptive Biotechnologies has higher revenue and earnings than bluebird bio. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than bluebird bio, indicating that it is currently the more affordable of the two stocks.

Summary

Adaptive Biotechnologies beats bluebird bio on 9 of the 13 factors compared between the two stocks.